John Fox, MD, MHA: I once thought that cancer, or oncology, would be the last bastion for fee-for-service payments because of the incredible complexity of cancer, the number of the different types of cancer, and the different stages of cancer. But we’ve moved into an era now where CMMI, the Center for Medicare & Medicaid Innovation, has put together an Oncology Care Model (OCM) where they’re asking providers to go at risk for the total cost of care—not just cancer care, but all cancer care or all costs for patients who have cancer.
For providers who are at risk for the total cost of care who are in the OCM, there is the potential that providers could withhold appropriate therapy, or give substandard therapy, for the sake of maximizing their revenue. So now, instead of a revenue center, patients have become a cost center. It’s critically important to have quality metrics built into these programs to ensure that we don’t sacrifice patient outcomes, whether it be quality of life or longevity of life, in these alternative payment models.
There have been a number of studies that have been published that have shown, for example, that pathways can reduce the total cost of cancer care. About 75% of that savings is due to the drugs themselves, but there are many other ways of reducing the cost of cancer care, such as through avoidable emergency room visits, avoidable hospitalizations through same-day access to healthcare services, and nurse triage programs that steer the patient to the office instead of to the emergency room or the hospital.
Another example is through palliative care programs. Dr Janet Temel published (from Massachusetts General Hospital, 7 years ago) that adding palliative care to non—small cell lung cancer treatment not only improved longevity of life by, on average 2.5months, but also improved quality of life and reduced depression. I’d say that if palliative care were a drug, everybody in the country would be on that drug. So, I think the point is that palliative care and advanced care planning are built into quality metrics. They’re built into the OCM 13-point care plan, and again, they’re intended to ensure that the patients’ preferences are taken into account and that they aren’t pushed aside out of financial interests on the part of the provider.
In the OCM, from CMS (Centers for Medicare & Medicaid Services), providers are at risk for the total cost of care in patients who have non—small cell lung cancer. There are a lot of challenges for a health plan like ours (that’s also participated in an OCM) to do a total-cost-of-care model. So, for common types of cancer (for breast, lung, colon), we do have incentives for providers, but they’re more centered around ensuring that patients have advanced care planning, they’re involved in palliative care, and that we reduce the costs associated with avoidable emergency room visits and hospitalizations.
There can be multiple types of incentives. They don’t all have to be around the total cost of care, and they don’t have to be around drug selection. As I said, there are many ways of reducing the cost of care. We’ve chosen to focus on avoidable hospitalizations and emergency room visits, and those services that have been shown to reduce the cost of care, including palliative care and advanced care planning.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More